PD-1 inhibitors with other drugs for EBV-related diseases
Part of Infections clinical trials.
This trial tests a combination of four drugs (PD-1 inhibitor, tenofovir, chidamide, and lenalidomide) for people with Epstein-Barr virus (EBV) infections that are causing symptoms. It aims to see if this combination can control the virus and improve health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an EBV infection, such as infectious mononucleosis or chronic active EBV, with a high level of the virus in your blood.
- You must be 75 years old or younger and able to care for yourself (ECOG score 0-2).
- Your doctor expects you to live at least 3 more months.
- You must be willing and able to come to the clinic for follow-up visits.
- You cannot have serious liver, kidney, bone marrow, heart, or other major health problems.
- You must not have HIV, active hepatitis B or C, syphilis, or severe infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs for patients with a type of lymphoma that is linked to the Epstein-Barr virus and has come back or not responded to previous treatment. The goal is to see if this combination can help control the disease.
This trial studies whether a specific treatment (a chemotherapy-based induction plan plus a PD-1 antibody) can improve outcomes in adults with lymphoma-associated HLH caused by Epstein-Barr virus (EBV). It aims to better control the overactive immune disease driving HLH and lymphoma.
This trial tests a new immune therapy for people with Epstein-Barr virus (EBV)-related lymphoproliferative diseases, including chronic active EBV and conditions that can occur after an organ or stem cell transplant. It aims to see if the therapy can safely control the disease.
This trial tests two drugs, golidocitinib and selinexor, given together to treat chronic active Epstein-Barr virus disease (CAEBVD). The goal is to see if this combination can help control the disease better than current options.
This trial tests a new mRNA-based treatment for people with Epstein-Barr virus (EBV) related diseases, such as certain cancers or EBV illness after a transplant. The goal is to see if the treatment can help your immune system fight the virus and the disease.
This Phase 1 study tests an immune-cell therapy made to recognize EBV (a common virus) in people whose lymphoma contains EBV. It may help control EBV-driven cancers, especially when standard treatment isn’t working or can’t be used.
Hear when a new Epstein-Barr Virus (EBV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.